Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (November 2024)
16 slides from Integral Diagnostics's shareholder meeting presentation, Nov 1, 2024
Slide 1: 2024 Annual General Meeting – CEO's Address and Presentation
Integral Diagnostics Limited 2024 Annual General Meeting – CEO’s Address and Presentation Ladies and gentlemen, I am proud to be talking to you today about Integral Diagnostics, the work we do for patients and referrers in Australia and New Zealand, and our financial performance in FY24. In particul
Slide 2: Continued Recovery in DI Industry Growth Rates: Australia
The Noosa PET will be the 8th PET-CT in the IDX group and the 1st PET-CT facility to service our Sunshine Coast patients. Continued Recovery in DI Industry Growth Rates: Australia Industry growth rates have come back solidly, and are now plateauing above long term averages for both the number of tes
Slide 3: YTD September FY25 Trading Update
The regulatory authorities in New Zealand determined that non-arms length referral practices by referrers who own interests in radiology practices are acceptable. In response, IDX has pursued several strategic initiatives, including a broadening of our referrer base in New Zealand to include more GP
Slide 4: There are 2 core components to our strategy
There are 2 core components to our strategy: • Grow our existing business and margin – drive organic earnings, accelerate use of teleradiology, digital and AI to improve the patient experience and clinical efficiency, to drive our ESG initiatives, and to always lead through our values. • Selectively
Slide 5: Attractive Proposed Merger Rationale
Attractive Proposed Merger Rationale If the proposed merger is approved and implemented, it will significantly enhance scale for the combined business, provide a platform to drive best-in-class clinical outcomes, have compelling financial metrics, and positions the combined entity well for future gr
Slide 6: Managing Director & CEO Presentation
MANAGING DIRECTOR & CEO PRESENTATION Dr Ian Kadish
Slide 7: The IDX Difference
THE IDX DIFFERENCE • Values-driven culture - Put patients first always. - Demonstrate medical leadership, including specialty expertise valued by referrers. - Ensure everyone counts - all 1,977 employees. - Endeavour to create value for shareholders and all stakeholders over time. - Embrace change i
Slide 8: IDX Today - Group Overview – June 2024
IDX TODAY - GROUP OVERVIEW – JUNE 2024 Victoria Queensland Western Australia New Zealand Queensland Geographic Market Victoria Victoria & NSW Queensland Queensland Western Australia New Zealand & NSW Ballarat, Geelong, Albury, Wodonga, Sunshine Coast, Gold Coast, Warrnambool and Wangaratta, Brisbane
Slide 9: Continued Recovery in DI Growth Rates: Australia
CONTINUED RECOVERY IN DI GROWTH RATES: AUSTRALIA Industry growth 20.0% 15.0% 10.0% 5.0% 0.0% (5.0%) (10.0%) Jun 2021 Jun 2015 Dec 2015 Jun 2016 Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2022 Jun 2023 Jun 2024 Dec 2014 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Mar 2023 Dec 2023 Mar
Slide 10: Regulatory Environment Update
REGULATORY ENVIRONMENT UPDATE Australia Key Medicare Changes 1 July 2024 MRI Licences • Indexation of 3.5% on all diagnostic imaging services (excluding • On 1 November 2022, the Federal government de-regulated MRI nuclear imaging services). services in regional and rural areas, defined as Modified
Slide 11: Regulatory Environment Update (Continued)
REGULATORY ENVIRONMENT UPDATE (CONTINUED) New Zealand Skills Shortages in Australia and New Zealand • There is limited indexation of pricing in New Zealand, however we • International medical graduates (radiologists and referring have received CPI like increases commencing in December 2023 doctors)
Slide 12: YTD September FY25 Trading Update
YTD SEPTEMBER FY25 TRADING UPDATE Q1 FY25 FY25 Capex, Depreciation and Finance Costs • Groupwide organic revenue growth of 8.6% vs pcp, for the financial year For FY25 IDX (excluding Capitol Health Limited) expects: to 30 September 2024, being 6.8% adjusted for working days. • Replacement and growth
Slide 13: Management's Strategy – Good Medicine Is Good Business
MANAGEMENT’S STRATEGY – GOOD MEDICINE IS GOOD BUSINESS 1 Grow Existing Business and Margin 2 Strategic Mergers & Acquisitions Strategy Accelerate use of Drive organic earnings teleradiology, digital Drivers of growth, including through As balance sheet capacity permits, consider and AI to improve th
Slide 14: Proposed Merger with Capitol Health Limited Vision for MergeCo
PROPOSED MERGER WITH CAPITOL HEALTH LIMITED Combination of two highly complementary diagnostic imaging businesses to realise significant and enduring benefits for all of our combined patients, doctors and shareholders ✓ Creates a leader in ANZ diagnostic Vision for MergeCo imaging, with significant
Slide 15: Attractive Proposed Merger Strategic Rationale and Financial Benefits
ATTRACTIVE PROPOSED MERGER STRATEGIC RATIONALE AND FINANCIAL BENEFITS ✓ Combination of two highly complementary footprints into a more geographically diversified portfolio Significantly ✓ Combined group will have a materially greater financial profile enhanced scale ✓ Nationwide footprint of 151 cli
Slide 16: Disclaimer
DISCLAIMER 1. Some of the information contained in this 3. Past performance of IDX cannot be relied upon 5. Reliance should not be placed on the presentation contains “forward-looking as an indicator of (and provides no guidance as information or opinions contained in this statements” which may not
Integral Diagnostics — Shareholder Meeting (November 2024) on 6ix